1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,650 | 9,750 | 23:00 | |
| 9,500 | 9,850 | 22:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Elicio Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Mo | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.04. | Elicio Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 16.04. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 1 | GlobeNewswire (USA) | ||
| 25.03. | BayWa r.e, Elicio and BW Ideol open Buchan hub | 65 | reNews | ||
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.03. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 4 | GlobeNewswire (USA) | ||
| 16.03. | Elicio Therapeutics kündigt "At-the-Market"-Aktienprogramm im Volumen von 100 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 12.03. | Elicio Therapeutics reports FY GAAP EPS of -$2.58 | 2 | Seeking Alpha | ||
| 12.03. | Elicio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.03. | Elicio Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 12.03. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.03. | Rodman & Renshaw initiates Elicio Therapeutics stock with buy rating | 1 | Investing.com | ||
| 09.03. | Rodman & Renshaw startet Coverage für Elicio Therapeutics mit Kaufempfehlung | 3 | Investing.com Deutsch | ||
| 18.02. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 8 | GlobeNewswire (USA) | ||
| 16.01. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 10 | GlobeNewswire (USA) | ||
| 19.11.25 | Elicio Therapeutics appoints Marc Wolfgang as chief technology officer | 1 | Investing.com | ||
| 19.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer | 476 | GlobeNewswire (Europe) | BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 13.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | 245 | GlobeNewswire (Europe) | In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC"), fewer disease progressions and deaths than projected have been observed as... ► Artikel lesen | |
| 07.11.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC | 285 | GlobeNewswire (Europe) | SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002... ► Artikel lesen | |
| 18.09.25 | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 262 | GlobeNewswire (Europe) | BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,485 | -0,34 % | NanoRepro: Mit Elan gestartet | "Wir sind auf einem guten Weg", sagt Lisa Jüngst, CEO von NanoRepro, am Ende ihrer Präsentation auf der Frühjahrskonferenz in Frankfurt. Die Aufgabenstellung könnte dabei ambitionierter kaum sein. Immerhin... ► Artikel lesen | |
| OCUGEN | 1,270 | +1,11 % | Ocugen Aktie explodiert nach unten: Wie tief geht es noch? | ||
| VIKING THERAPEUTICS | 26,950 | +0,94 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,420 | +0,71 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results |
TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| BIOCRYST PHARMACEUTICALS | 8,242 | +9,89 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release | ||
| IBIO | 1,437 | +5,12 % | iBio, Inc.: iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors | SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,650 | -1,08 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,990 | -2,94 % | RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | 2025 was a year of tenacity, strategic transactions and building traction for RedHill
Talicia® business transformed:
Formation of Talicia Holdings Inc. (THI) and... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,435 | +2,43 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| MANNKIND | 2,762 | -1,29 % | MannKind Reports First Quarter 2026 Financial Results and Provides Business Update | Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming launchesSettlement of senior convertible notes of $36.3M Program... ► Artikel lesen | |
| ALDEYRA | 1,420 | -2,74 % | Aldeyra Therapeutics: Aufsichtsratsmitglied Martin J. Joyce tritt nicht zur Wiederwahl an | ||
| TRAWS PHARMA | 1,750 | +4,17 % | Traws Pharma, Inc.: Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections | NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,420 | -2,81 % | Coherus Oncology, Inc.: Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update | - LOQTORZI net revenue of $11.8 million in Q1 2026 - - Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections... ► Artikel lesen |
Das Unternehmen ELICIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,150 (+1,67 %) liegt der Kurs bei 9,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.